{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:29:14Z","timestamp":1792045754615,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T00:00:00Z","timestamp":1476403200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.vaccine.2016.08.057","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T16:36:21Z","timestamp":1473784581000},"page":"5442-5448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications"],"prefix":"10.1016","volume":"34","author":[{"given":"Erin","family":"Sparrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamud","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siranda","family":"Torvaldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Newall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.08.057_b0005","unstructured":"The World Health Organization Website. Pandemic influenza vaccine manufacturing process and timeline. <http:\/\/www.who.int\/csr\/disease\/swineflu\/notes\/h1n1_vaccine_20090806\/en\/>."},{"key":"10.1016\/j.vaccine.2016.08.057_b0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2334-13-81","article-title":"Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis","volume":"13","author":"Kelso","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.057_b0015","article-title":"Total economic consequences of an influenza outbreak in the United States","author":"Prager","year":"2016","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2016.08.057_b0020","unstructured":"Cox N. Pandemic influenza vaccines: lessons learned from the H1N1 influenza pandemic. Presentation at the second WHO consultation on the GAP for influenza vaccines 12\u201314 July 2011. <http:\/\/www.who.int\/influenza_vaccines_plan\/resources\/cox.pdf> [accessed 4 June 2016]."},{"issue":"3","key":"10.1016\/j.vaccine.2016.08.057_b0025","first-page":"95","article-title":"Changes in and shortcomings of drug stockpiling, vaccine development and related policies during outbreaks of avian influenza A H5N1, H1N1, and H7N9 among humans","volume":"7","author":"Mei","year":"2013","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.vaccine.2016.08.057_b0030","unstructured":"Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile. Report from WHO scientific consultation, 1\u20133 October 2007. <http:\/\/www.who.int\/csr\/resources\/publications\/WHO_HSE_EPR_GIP_2008_1d.pdf> [accessed 4 June 2016]."},{"issue":"26","key":"10.1016\/j.vaccine.2016.08.057_b0035","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: shifting to better vaccines","volume":"34","author":"Berlanda Scorza","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.057_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.12.005","article-title":"Universal influenza vaccines: a realistic option?","author":"de Vries","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"26","key":"10.1016\/j.vaccine.2016.08.057_b0045","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/j.vaccine.2016.02.078","article-title":"Committee WPDfVA, Committee: WPDfVPDA. Report from the World Health Organization\u2019s Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7\u20139th Sep 2015","volume":"34","author":"Giersing","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2016.08.057_b0050","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3201\/eid2206.151037","article-title":"Debate regarding oseltamivir use for seasonal and pandemic influenza","volume":"22","author":"Hurt","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2016.08.057_b0055","doi-asserted-by":"crossref","first-page":"e9106","DOI":"10.1371\/journal.pone.0009106","article-title":"New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets","volume":"5","author":"Friesen","year":"2010","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2016.08.057_b0060","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1073\/pnas.1319058110","article-title":"A common solution to group 2 influenza virus neutralization","volume":"111","author":"Friesen","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.vaccine.2016.08.057_b0065","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.chom.2014.04.009","article-title":"Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure","volume":"15","author":"Tharakaraman","year":"2014","journal-title":"Cell Host Microbe"},{"issue":"6044","key":"10.1016\/j.vaccine.2016.08.057_b0070","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.08.057_b0075","unstructured":"EU clinical trials register. Clinical trials for eudract_number:2013-002185-39. <https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-002185-39>."},{"key":"10.1016\/j.vaccine.2016.08.057_b0080","unstructured":"Celltrion Website. Press Release: Celltrion announces positive data from phase 1 trial of a novel therapeutic antibody CT-P27. <www.celltrion.com\/en\/company\/notice_view.asp?idx=414&code=ennews&intNowPage=1&menu_num=&align_year=all>."},{"key":"10.1016\/j.vaccine.2016.08.057_b0085","unstructured":"Press Release. FGI successfully completes phase 1A first-in-human clinical trial, 4 November 2011. <http:\/\/finance.yahoo.com\/news\/FGI-Successfully-Completes-iw-2405166867.html>."},{"key":"10.1016\/j.vaccine.2016.08.057_b0090","unstructured":"McAuliffe J, Benjamin E, Wachter L, Palmer-Hill F, Martinez J, Haller L, et al. Pre-clinical studies of a novel monoclonal antibody for treatment of severe influenza A infection. Abstract: Pre-clinical studies of a novel monoclonal antibody for treatment of severe influenza A infection. 4th Influenza research & development conference July 8\u201310. Boston, USA; 2015."},{"key":"10.1016\/j.vaccine.2016.08.057_b0095","unstructured":"AstraZeneca Website. Press Release: MedImmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza. <https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2016\/Medimmune-receives-fast-track-designation-in-the-US-for-MEDI8852-for-treatment-of-patients-hospitalised-with-influenza-A-07032016.html>."},{"key":"10.1016\/j.vaccine.2016.08.057_b0100","article-title":"Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A","volume":"1\u20137","author":"Gupta","year":"2016","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.vaccine.2016.08.057_b0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/irv.12293","article-title":"Overview of the 3rd ISIRV-antiviral group conference \u2013 advances in clinical management","volume":"9","author":"Hurt","year":"2015","journal-title":"Influenza Other Respir Viruses"},{"issue":"7","key":"10.1016\/j.vaccine.2016.08.057_b0110","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/infdis\/jiu539","article-title":"Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza","volume":"211","author":"Ramos","year":"2015","journal-title":"J Infect Dis"},{"issue":"28","key":"10.1016\/j.vaccine.2016.08.057_b0115","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1073\/pnas.0911806107","article-title":"Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses","volume":"107","author":"Grandea","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.08.057_b0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2016.02.021","article-title":"Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks","volume":"5","author":"Wollacott","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2016.08.057_b0130","unstructured":"Vistera website. VIS410 for influenza A. <http:\/\/www.visterrainc.com\/pipeline\/vis410.html>."},{"key":"10.1016\/j.vaccine.2016.08.057_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2016.05.013","article-title":"Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies","author":"Balasingam","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.057_b0140","unstructured":"US FDA guidance for industry, influenza: developing drugs for treatment and\/or prophylaxis; 2011."},{"key":"10.1016\/j.vaccine.2016.08.057_b0145","first-page":"CD008965","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","volume":"1","author":"Jefferson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.vaccine.2016.08.057_b0150","first-page":"CD008965","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","author":"Jefferson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2016.08.057_b0155","unstructured":"WHO statement on public disclosure of clinical trial results. <http:\/\/www.who.int\/ictrp\/results\/WHO_Statement_results_reporting_clinical_trials.pdf?ua=1> [accessed 6 June 2016]."},{"issue":"2","key":"10.1016\/j.vaccine.2016.08.057_b0160","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/21645515.2015.1079676","article-title":"Immunological considerations for developing antibody therapeutics for Influenza A","volume":"12","author":"Chan-Hui","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2016.08.057_b0165","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","article-title":"Industrialization of mAb production technology: the bioprocessing industry at a crossroads","volume":"1","author":"Kelley","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.vaccine.2016.08.057_b0170","unstructured":"MedImmune Website: MEDI8897 receives fast track designation by the FDA for the prevention of respiratory disease caused by RSV in infants. <https:\/\/www.medimmune.com\/about-us\/media\/medi8897-receives-fast-track-designation-by-the-fda-for-the-prevention-of-respiratory-disease-caused-by-rsv-in-infants-20150409.html>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16307447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16307447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T12:44:16Z","timestamp":1568378656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16307447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":33,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0264410X16307447"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 World Health Organization; licensee Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}